Latest News & Updates

Breaking News

  • 3 hours ago

  • Vaibhavi M.

Roche’s Phase III MAJESTY Study Shows Gazyva Superior To Tacrolimus In Primary Membranous Nephropathy
Breaking News
Oncotelic And Sapu Bioscience Expand Global IP Protection For OT-101 Across CNS And Oncology

Vaibhavi M.

Cue Biopharma Appoints Lucinda Warren To Chief Financial And Business Officer, Strengthening Financial And Strategic Leadership

Vaibhavi M.

BridgeBio Reports Positive Phase 3 PROPEL 3 Results For Infigratinib In Achondroplasia

Vaibhavi M.

Kane Biotech Restarts North American Sales Of Revyve® Wound Gel, Appoints Business Development Leaders

Vaibhavi M.

Other trending news you may like to read

Roche’s Phase III MAJESTY Study Shows Gazyva Superior To Tacrolimus In Primary Membranous Nephropathy

Roche’s Phase III MAJESTY trial shows Gazyva outperforms tacrolimus in primary membranous nephropathy.

Vaibhavi M.

Pharma Now

Oncotelic And Sapu Bioscience Expand Global IP Protection For OT-101 Across CNS And Oncology

Oncotelic and Sapu expand global IP protection for OT-101 across CNS, oncology, and drug delivery technologies.

Vaibhavi M.

Pharma Now

Cue Biopharma Appoints Lucinda Warren To Chief Financial And Business Officer, Strengthening Financial And Strategic Leadership

Cue Biopharma names Lucinda Warren CFBO, combining finance and business leadership to support autoimmune pipeline growth.

Vaibhavi M.

Pharma Now

BridgeBio Reports Positive Phase 3 PROPEL 3 Results For Infigratinib In Achondroplasia

BridgeBio reports positive Phase 3 PROPEL 3 results for oral infigratinib in children with achondroplasia.

Vaibhavi M.

Pharma Now